DT-Web

DB01377 - Magnesium oxide


Identification
Name Magnesium oxide
Accession Number DB01377
Type small molecule
Description Magnesium oxide is an inorganic compound that occurs in nature as the mineral periclase. In aqueous media combines quickly with water to form magnesium hydroxide. It is used as an antacid and mild laxative and has many nonmedicinal uses. [PubChem]
Structure
MOL SDF PDB SMILES InChI
Categories (*)
Molecular Weight 40.304
Groups approved
Monoisotopic Weight 39.97995652
Pharmacology
Indication Magnesium hydroxide is used as a laxative to relieve occasional constipation (irregularity) and as an antacid to relieve indigestion, sour stomach, and heartburn.
Mechanism of action The term "Milk of Magnesia" was first used to describe a white aqueous, mildly alkaline suspension of magnesium hydroxide formulated at about 8%w/v. Milk of magnesia is primarily used to alleviate constipation, but can also be used to relieve indigestion and heartburn. When taken internally by mouth as a laxative, the osmotic force of the magnesia suspension acts to draw fluids from the body and to retain those already within the lumen of the intestine, serving to distend the bowel, thus stimulating nerves within the colon wall, inducing peristalsis and resulting in evacuation of colonic contents. Magnesium supplements have also been shown to reduce platelet aggregation by inhibiting in the influx of calcium, a crucial component of platelet aggregation.
Absorption Not Available
Protein binding Not Available
Biotransformation Not Available
Route of elimination Not Available
Toxicity Not Available
Affected organisms Not Available
Interactions
Drug Interactions
Drug Mechanism of interaction
Amprenavir The antiacid decreases the absorption of amprenavir
Atazanavir This gastric pH modifier decreases the levels/effects of atazanavir
Chloroquine The antiacid decreases the absorption of chloroquine
Ciprofloxacin Formation of non-absorbable complexes
Clodronate Formation of non-absorbable complexes
Dapsone Formation of non-absorbable complexes
Delavirdine The antiacid decreases the effect of delavirdine
Demeclocycline Formation of non-absorbable complexes
Doxycycline Formation of non-absorbable complexes
Etidronic acid Formation of non-absorbable complexes
Fosamprenavir The antiacid decreases the absorption of amprenavir
Gatifloxacin Formation of non-absorbable complexes
Gemifloxacin Formation of non-absorbable complexes
Grepafloxacin Formation of non-absorbable complexes
Ibandronate Formation of non absorbable complexes
Indinavir The antacid decreases the absorption of indinavir
Itraconazole The antacid, magnesium oxide, may decrease the effect of itraconazole by decreasing its absorption.
Ketoconazole The antacid, magnesium oxide, may decrease the effect of ketoconazole by decreasing its absorption.
Levofloxacin Formation of non-absorbable complexes
Minocycline Formation of non-absorbable complexes
Moxifloxacin Formation of non-absorbable complexes
Norfloxacin Formation of non-absorbable complexes
Ofloxacin Formation of non-absorbable complexes
Tiludronate The divalent cation of oral Magnesium oxide may significantly decrease the absorption of Tiludronate by forming a nonabsorbable chelate. Oral dosing should be separated by at least 2 hours.
Trovafloxacin Magnesium may decrease the absorption of orally administered Trovafloxacin. Administer Trovafloxacin 2 hours before or 6 hours after a dose of the magnesium containing agent to minimize the interaction.
Food Interactions Not Available

Predictions


Id Partner name Gene Name Score
↑